東光化工(01702.HK)中期純利1.48億元 同比增長6.82%
格隆匯8月26日丨東光化工(01702.HK)發佈公吿,截至2022年6月30日止六個月,報吿期間,集團收益錄得上漲。集團錄得溢利同比增長6.1%至約人民幣1.51億元,主要由於集團總體毛利增加、行政開支及融資成本減少。收入同比增長32.8%至約人民幣17.203億元,主要由於尿素平均售價上升。報吿期間,集團的尿素產品的平均售價約每噸人民幣2567元,較2021年同期約每噸人民幣1928元增加約33.1%。報吿期內,公司擁有人應占溢利人民幣1.48億元,同比增長6.82%,基本每股盈利人民幣23.8分。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.